Information Provided By:
Fly News Breaks for January 8, 2020
Jan 8, 2020 | 11:57 EDT
Raymond James analyst David Novak upgraded Leap Therapeutics to Outperform from Market Perform with a $2.50 price target. With a "strong" partner in BeiGene (BGNE) and a recapitalized balance sheet removing the financial overhang, Leap is now well positioned to unlock potential value from DKN-01 throughout the next year, Novak tells investors in a research note. The analyst is impressed with the company's ability to attract a "marquee partner" in BeiGene and believes Leap is well capitalized into 2021.